Newsfeeds - Spark Newswire

2 minute read

Albireo To Showcase New Data At AASLD The Liver Meeting On Nov. 16

Today, 11:48 AM

Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of data at the American Association for the Study of Liver Diseases (AASLD) The

ALBO

1 minute read

Wedbush Maintains Outperform on Albireo Pharma, Raises Price Target to $84

By vishwanath@benzinga.com

Today, 11:48 AM

Wedbush analyst Liana Moussatos maintains Albireo Pharma (NASDAQ:ALBO) with a Outperform and raises the price target from $82 to $84.

ALBO

3 minute read

FDA
News

Albireo Announces Bylvay (odevixibat) Now Available In Germany

By Benzinga Newsdesk

Today, 11:48 AM

Albireo Pharma, Inc. (NASDAQ:ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Bylvay (odevixibat), the first drug approved in Europe for the treatment of all types

ALBO

1 minute read

Albireo Pharma Sells Bylvay-Associated PRV For $105M

By Vandana Singh

Today, 11:48 AM

Albireo Pharma Inc (NASDAQ:ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV…

ALBO

2 minute read

Albireo Sells Priority Review Voucher For $105M

By Bill Haddad

Today, 11:48 AM

– PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat) in July – – Non-dilutive capital further strengthens the Company's financial position – BOSTON, Sept. 07,

ALBO

2 minute read

Earnings

Looking into Albireo Pharma’s Return on Capital Employed

By Benzinga Insights

Today, 11:48 AM

After pulling data from Benzinga Pro it seems like during Q2, Albireo Pharma (NASDAQ:ALBO) posted sales of $2.43 million. Earnings were up 16.96%, but Albireo Pharma still reported an overall loss of $33.03 million.

ALBO

1 minute read

Albireo Pharma Q2 EPS $(1.90) Beats $(1.96) Estimate, Sales $2.43M Beat $1.98M Estimate

By Benzinga Newsdesk

Today, 11:48 AM

Albireo Pharma (NASDAQ:ALBO) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(1.96) by 3.06 percent. This is a 37.68 percent decrease over losses of $(1.38) per share from the

ALBO

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

Today, 11:48 AM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI

4 minute read

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

By Shanthi Rexaline

Today, 11:48 AM

The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdicts.

ALBO

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline

Today, 11:48 AM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV